Advanced in Primitive Neuroectodermal Tumor (PNET)

Dr. Roy Strowd

Neurology | Hematology | Oncology
Wake Forest University Health Sciences
Medical Ctr Blvd, 
Winston Salem, NC 
Offers Telehealth
16 Years of Experience
Advanced in Primitive Neuroectodermal Tumor (PNET)
Wake Forest University Health Sciences
Medical Ctr Blvd, 
Winston Salem, NC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Roy Strowd is a Neurologist and a Hematologist in Winston Salem, North Carolina. Dr. Strowd has been practicing medicine for over 16 years and is rated as an Advanced provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). His top areas of expertise are Glioma, Astrocytoma, Brain Tumor, Glioblastoma, and Deep Brain Stimulation.

His clinical research consists of co-authoring 204 peer reviewed articles and participating in 16 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Year
2009
Specialties
Neurology
Hematology
Oncology
Licenses
Psychiatry & Neurology in NC
Hospital Affiliations
Wilkes Regional Medical Center
North Carolina Baptist Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
AmeriHealth
  • EPO
  • HMO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 3 Less Insurance Carriers -

Locations

WAKE FOREST UNIVERSITY HEALTH SCIENCES
Medical Ctr Blvd, Winston Salem, NC 27157

Additional Areas of Focus

Dr. Strowd has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

15 Clinical Trials

A Phase II Basket Trial of Glutaminase Inhibitor (BEGIN) Telaglenastat (CB-839) HCL in Patients With NF1 Aberrations, NF1 Mutant Malignant Peripheral Nerve Sheath Tumors (MPNST), KEAP1/NRF2 and LKB1 Aberrant Tumors
A Phase II Basket Trial of Glutaminase Inhibitor (BEGIN) Telaglenastat (CB-839) HCL in Patients With NF1 Aberrations, NF1 Mutant Malignant Peripheral Nerve Sheath Tumors (MPNST), KEAP1/NRF2 and LKB1 Aberrant Tumors
Enrollment Status: Active_not_recruiting
Publish Date: September 19, 2025
Intervention Type: Procedure, Drug, Other
Study Drug: Telaglenastat Hydrochloride
Study Phase: Phase 2
Phase 0/I Study of AMG 232 (KRT 232) Concentrations in Brain Tissue in Patients With Recurrent Glioblastoma and of AMG 232 (KRT 232) in Combination With Radiation in Patients With Newly Diagnosed Glioblastoma and Unmethylated MGMT Promoters
Phase 0/I Study of AMG 232 (KRT 232) Concentrations in Brain Tissue in Patients With Recurrent Glioblastoma and of AMG 232 (KRT 232) in Combination With Radiation in Patients With Newly Diagnosed Glioblastoma and Unmethylated MGMT Promoters
Enrollment Status: Terminated
Publish Date: August 20, 2025
Intervention Type: Procedure, Drug, Radiation
Study Drug: KRT-232
Study Phase: Phase 1
Safety and Efficacy Study of Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas
Safety and Efficacy Study of Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas
Enrollment Status: Active_not_recruiting
Publish Date: August 07, 2025
Intervention Type: Drug, Radiation
Study Drugs: Epacadostat, Bevacizumab
Study Phase: Phase 2
Open Label Safety Study of Solriamfetol to Promote Wakefulness and Improve Cognition and Quality of Life in Patients With Primary Gliomas
Open Label Safety Study of Solriamfetol to Promote Wakefulness and Improve Cognition and Quality of Life in Patients With Primary Gliomas
Enrollment Status: Terminated
Publish Date: March 14, 2025
Intervention Type: Drug
Study Drug: Soliramfetol
Study Phase: Phase 2
Phase I Study of Neoadjuvant GMCI Plus Immune Checkpoint Inhibitor Combined With Standard of Care for Newly Diagnosed High-Grade Gliomas
Phase I Study of Neoadjuvant GMCI Plus Immune Checkpoint Inhibitor Combined With Standard of Care for Newly Diagnosed High-Grade Gliomas
Enrollment Status: Completed
Publish Date: February 14, 2025
Intervention Type: Radiation, Biological, Other, Drug
Study Drugs: AdV-tk, Valacyclovir, Temozolomide, Nivolumab
Study Phase: Phase 1
A Phase II Study of Binimetinib in Combination With Encorafenib in Adults With Recurrent BRAF V600-Mutated High-Grade Astrocytoma or Other Primary Brain Tumor
A Phase II Study of Binimetinib in Combination With Encorafenib in Adults With Recurrent BRAF V600-Mutated High-Grade Astrocytoma or Other Primary Brain Tumor
Enrollment Status: Terminated
Publish Date: October 31, 2024
Intervention Type: Biological, Drug
Study Drugs: Encorafenib, Binimetinib
Study Phase: Phase 2
tGLI1 as a Therapeutic Target in Brain Metastases: A Window of Opportunity Study in Breast Cancer Brain Metastases and Primary Gliomas
tGLI1 as a Therapeutic Target in Brain Metastases: A Window of Opportunity Study in Breast Cancer Brain Metastases and Primary Gliomas
Enrollment Status: Terminated
Publish Date: September 19, 2024
Intervention Type: Other, Drug
Study Drug: Ketoconazole
Study Phase: Early Phase 1
Phase I Study to Determine the Safety and Tolerability of the Oral Microtubule Destabilizer BAL101553 in Combination With Standard Radiation in Patients With MGMT Promoter Unmethylated Newly Diagnosed Glioblastoma
Phase I Study to Determine the Safety and Tolerability of the Oral Microtubule Destabilizer BAL101553 in Combination With Standard Radiation in Patients With MGMT Promoter Unmethylated Newly Diagnosed Glioblastoma
Enrollment Status: Terminated
Publish Date: June 24, 2024
Intervention Type: Drug, Radiation
Study Drug: BAL101553
Study Phase: Phase 1
Feasibility Study on Laser Interstitial Thermal Therapy Ablation for the Treatment of Newly Diagnosed Glioblastoma
Feasibility Study on Laser Interstitial Thermal Therapy Ablation for the Treatment of Newly Diagnosed Glioblastoma
Enrollment Status: Terminated
Publish Date: April 12, 2024
Intervention Type: Device, Drug
Study Phase: Phase 1
A Pilot Study Using Ultrasound for the Detection of Taxane-Induced Peripheral Neuropathy
A Pilot Study Using Ultrasound for the Detection of Taxane-Induced Peripheral Neuropathy
Enrollment Status: Completed
Publish Date: April 08, 2024
Intervention Type: Diagnostic test, Procedure, Other
Study Phase: Not Applicable
A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Phase 2 Dose-Response Study to Determine Safety and Effectiveness of Two Concentrations of NFX-179 Gel in Subjects With Cutaneous Neurofibromas
A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Phase 2 Dose-Response Study to Determine Safety and Effectiveness of Two Concentrations of NFX-179 Gel in Subjects With Cutaneous Neurofibromas
Enrollment Status: Completed
Publish Date: November 18, 2023
Intervention Type: Drug
Study Drug: NFX-179
Study Phase: Phase 2
A Biospecimen Collection Study to Evaluate the Pharmacokinetic, Pharmacodynamic, and Resistance Profile to Trametinib and Dabrafenib in BRAF-V600E Mutated Recurrent Gliomas
A Biospecimen Collection Study to Evaluate the Pharmacokinetic, Pharmacodynamic, and Resistance Profile to Trametinib and Dabrafenib in BRAF-V600E Mutated Recurrent Gliomas
Enrollment Status: Terminated
Publish Date: October 06, 2023
Intervention Type: Procedure
Randomized Pilot Study of Six Months Adjuvant Temozolomide (TMZ) vs No Adjuvant TMZ in Patients With Newly Diagnosed MGMT Methylated Glioblastoma (GBM) Following Standard Concurrent Radiation and TMZ
Randomized Pilot Study of Six Months Adjuvant Temozolomide (TMZ) vs No Adjuvant TMZ in Patients With Newly Diagnosed MGMT Methylated Glioblastoma (GBM) Following Standard Concurrent Radiation and TMZ
Enrollment Status: Withdrawn
Publish Date: August 10, 2022
Intervention Type: Other
Single-Arm, Open-Label Phase II Efficacy Study of First-in-Class HIF-2 Alpha Inhibitor, PT2385, for Patients With Recurrent Glioblastoma
Single-Arm, Open-Label Phase II Efficacy Study of First-in-Class HIF-2 Alpha Inhibitor, PT2385, for Patients With Recurrent Glioblastoma
Enrollment Status: Completed
Publish Date: May 09, 2022
Intervention Type: Drug, Other
Study Phase: Phase 2
Determining the Competence of the Immune System Over the First Year of Therapy in Patients With Glioma: A Battery of Quantitative, Qualitative and Functional Measures of Immune Readiness
Determining the Competence of the Immune System Over the First Year of Therapy in Patients With Glioma: A Battery of Quantitative, Qualitative and Functional Measures of Immune Readiness
Enrollment Status: Completed
Publish Date: October 29, 2021
Intervention Type: Biological, Other
View 14 Less Clinical Trials

201 Total Publications

Phase I study of NT-I7, a long-acting interleukin-7, in severe treatment-related lymphopenia following standard radiation and temozolomide for high-grade glioma.
Phase I study of NT-I7, a long-acting interleukin-7, in severe treatment-related lymphopenia following standard radiation and temozolomide for high-grade glioma.
Journal: Neuro-oncology advances
Published: July 24, 2025
Similar Doctors
Distinguished in Primitive Neuroectodermal Tumor (PNET)
Dr. Zachary K. Vaslow
Neurology
Distinguished in Primitive Neuroectodermal Tumor (PNET)
Dr. Zachary K. Vaslow
Neurology

The Moses H Cone Memorial Hospital Operating Corporation

501 N Elam Ave, 
Greensboro, NC 
 (24.9 miles away)
336-832-1100
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Zachary Vaslow is a Neurologist in Greensboro, North Carolina. Dr. Vaslow is rated as a Distinguished provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). His top areas of expertise are Metastatic Brain Tumor, Primitive Neuroectodermal Tumor (PNET), Posterior Fossa Tumor, and Astrocytoma. Dr. Vaslow is currently accepting new patients.

Glenn J. Lesser
Advanced in Primitive Neuroectodermal Tumor (PNET)
Dr. Glenn J. Lesser
Oncology | Hematology
Advanced in Primitive Neuroectodermal Tumor (PNET)
Dr. Glenn J. Lesser
Oncology | Hematology

Wake Forest University Health Sciences

Medical Ctr Blvd, 
Winston Salem, NC 
 (0.1 miles away)
336-716-2734
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Glenn Lesser is an Oncologist and a Hematologist in Winston Salem, North Carolina. Dr. Lesser is rated as an Elite provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). His top areas of expertise are Brain Tumor, Glioblastoma, Astrocytoma, Glioma, and Bone Marrow Aspiration. Dr. Lesser is currently accepting new patients.

Advanced in Primitive Neuroectodermal Tumor (PNET)
Dr. William J. Petty
Hematology Oncology | Hematology | Oncology
Advanced in Primitive Neuroectodermal Tumor (PNET)
Dr. William J. Petty
Hematology Oncology | Hematology | Oncology

Wake Forest University Health Sciences

365 Brookdale Dr, 
Statesville, NC 
 (39.5 miles away)
704-872-3630
Languages Spoken:
English
See accepted insurances
Accepting New Patients

William Petty is a Hematologist Oncology specialist and a Hematologist in Statesville, North Carolina. Dr. Petty is rated as a Distinguished provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). His top areas of expertise are Thymic Epithelial Tumor, Pleuropulmonary Blastoma, Lung Adenocarcinoma, Advanced Bronchoscopy, and Bone Marrow Aspiration. Dr. Petty is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Strowd's expertise for a condition
ConditionClose
View All 7 Distinguished Conditions
View All 27 Advanced Conditions
View All 51 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile